The prostate -specific antigen ( PSA ) promoter is known to be highly tissue specific. Although its tissue specificity has been confirmed, its efficiency of gene transcription is significantly lower compared to known nonspecific viral promoters. These lower levels of promoter activity therefore pose a problem when developing an efficacious gene vector for prostate cancer gene therapy. Thus, selecting an appropriate therapeutic gene and vector system to carry the gene driven by the PSA promoter ( PSAP ) is important. In the studies described here, a human immunodeficiency virus ( HIV ) -1 -based lentiviral vector carrying either the enhanced green fluorescent protein ( EGFP ) reporter or the diphtheria toxin A ( DTA ) gene was constructed. The results demonstrate that the PSA promoter in a lentiviral vector drives genes in prostate cells with satisfactory efficacy and specificity. The tissue -specific expression of the DTA protein efficiently eradicates LNCaP prostate cells in culture. We also infected prostate cancer cells and control cells carried by nude mice with the EGFP lentiviral vector. Significant numbers of EGFP -positive LNCaP cells were detected in all the mice bearing these tumors, but no EGFP -positive control cells were detected in any other mouse tissue. The high levels of expression in prostate cells, compared with the low levels of background expression in other cells, show that the PSAP -lentiviral vector could be a potential useful tool for gene therapy of metastatic prostate cancer. Cancer Gene Therapy ( 2001 ) 8, 628 -635 
P
rostate cancer is the second leading cause of cancer deaths in American men ( American Cancer Society, 1999, Internet www.cancer.org). Surgery, radiation, and hormonal therapies are currently the standard forms of treatment for prostate cancer. However, these conventional therapies are not adequate for fighting metastatic disease, especially those cases that are hormone-refractory. 1 -5 Thus, new treatments are needed to combat advanced forms of prostate cancer.
Prostate cancer cells express a well -characterized antigen, prostate -specific antigen (PSA ). PSA has been demonstrated to be a sensitive and specific tumor marker for cancer screening and assessment, 6 -8 and is used as an indicator of disease and response to prostate cancer therapy. 9 -12 PSA has highly restricted tissue distribution, and is expressed in normal epithelial cells of the prostate gland, which is the cell type in which most prostate tumors arise. Although the role of PSA in normal and neoplastic prostate cells is not well understood, the regulation machinery that enables PSA to be specifically expressed in prostate cancer cells could be very useful for constructing a tissue -specific vector to target metastatic cells.
The PSA promoter contains two sequence elements, one of approximately 550 base pairs (bp ) in length flanking the PSA gene, and the other, approximately 800 bp, located 3.9 kb upstream of the 550 -bp element. The PSA promoter has been extensively studied, and was cloned either from cell lines or patient samples. 13 -19 The PSA promoter sequence was isolated from a prostate cancer patient with high levels of serum PSA. The transcriptional activity and tissuespecific expression of this promoter were characterized, using the cytomegalovirus ( CMV ) immediate early promoter as a control. The results demonstrate that the patientderived PSA promoter is highly tissue -specific, and its transcriptional activity is approximately 5 -25% that of the CMV promoter, depending on the conditions for cell growth and concentration of androgen (e.g., dihydrotestosterone ) used. 18, 20 A DNA transfection method was used to deliver PSA promoter -based gene expression cassettes into prostate cells. Although this method is very useful for characterizing transcriptional potency and tissue -specific expression of this promoter, we found that only 5-20% cells were transfected. 20 Construction of a gene delivery vector with high efficacy is necessary for therapeutic applications.
The PSA promoter, along with a reporter gene, was inserted into a first-generation adenoviral vector. Gene delivery was significantly improved; however, the tissue specificity of the PSA promoter was decreased from over 400 -fold (comparing transfection of the PCR -producing prostate cells with transfection of other cell lines with plasmid vectors) to approximately 20-fold or even lower, 21 -23 which impedes usage of the constructed adenoviral vector, as a highly specific gene expression vector is essential for targeting metastatic prostate cancer cells in vivo. In such a context, testing other vectors is necessary. We tested human immunodeficiency virus ( HIV ) -1 -based lentiviral vectors, which have demonstrated several advantages: ( 1) the promoter in lentiviral vectors is very weak in the absence of HIV-1 Tat and Rev proteins, so the tissue specificity of the inserted gene expression cassette may not be affected; ( 2) the essential sequences required for viral packaging are short, so more than 8 kb of DNA can be inserted; (3 ) these vectors infect nondividing cells; and (4 ) these vectors can be pseudotyped with the vesicular stomatitis virus envelope G glycoprotein (VSV-G ) or other membrane proteins to increase vector infectivity and specificity. In the studies described here, we used the VSV-G pseudotyped lentiviral vector. Because VSV-G allows viral particles to bind to membrane phospholipids of target cells rather than to specific receptors, rates of infectivity are high, with a wide target spectrum. 24 The patient -derived PSA promoter was inserted into a plasmid containing the HIV-1 long terminal repeats (LTR ) and the virus package signal, and either the enhanced green fluorescent protein ( EGFP ) (Clontech, Palo Alto, CA ) or the diphtheria toxin A ( DTA ) gene was then inserted downstream of the PSA promoter in the plasmid. Using a three -piece transfection method, 24 lentiviral vectors with viral genomes containing either the PSAP -EGFP or PSAP -DTA expression cassettes were constructed ( Fig 1 ) and used to infect prostate and nonprostate cell lines.
MATERIALS AND METHODS

Cell lines and maintenance
The PSA -producing cell line, LNCaP, and the non -PSAproducing prostate cell line, DU145, were obtained from the American Type Culture Collection ( ATCC ) (Manassas, VA ). The R11 cell line was originally derived from a patient with renal cell carcinoma ( RCC ). 18 The oral tumor cell line, TU139, 25 was a gift from Dr. N. -H. Park, UCLA School of Dentistry, and HUVEC endothelial cells YU, CHEN, CHIU, ET AL: PROSTATE -SPECIFIC LENTIVIRAL GENE THERAPY VECTOR were provided by Dr. L. Li, George Washington University. All cell lines except HUVEC were maintained in RPMI medium with 10% fetal bovine serum from Gibco -BRL. The HUVEC cells were maintained in EBM medium with the addition of the EGM -2 growth hormone package purchased from BioWhitaker ( Walkersville, MD ).
Construction and preparation of lentiviral vectors
We used a cotransfection method described previously 24 to prepare lentiviral vectors. The required plasmids, including the transduction plasmids, VSV-G ( pVSV-G ) and the packaging plasmid ( pCMVÁR8.2vprx ), were used to cotransfect 293T cells by a calcium phosphate precipitation method (Fig 1 ) . Plasmid pCMVÁR8.2vprx carries genes required for assembly of lentiviral vectors, with deletion of the viral packaging signal and LTRs. To decrease nonspecific toxicity of the viral vectors, the vpr gene from the parental plasmid, pCMVÁR8.2, was mutated by oligodirected mutagenesis. The C -terminal 64 amino acids of Vpr were deleted from the packaging plasmid, pCMVR8.2, creating plasmid pCMVÁR8.2Vprx. 26 The transfected cells were washed 16 hours posttransfection before addition of fresh medium. Lentiviral vector released from the transfected cells was collected every 24 hours from day 2 postinfection for 4 days. The collected viral stocks were passed through 0.22 -M filters to remove cell debris. The titers of virus were estimated by measuring p24 Gag protein concentrations in viral stocks. Generally, the harvested virus stocks contained approximately 100 -1000 ng /mL of p24.
The control vector, a lentiviral vector carrying the CMV-EGFP expression cassette, was obtained from I.S.Y. Chen, UCLA School of Medicine. Its structure is similar to the previously reported lentiviral vector carrying the CMV-GFP expression cassette. 24, 27 Vector titration
All harvested viral vectors were subjected to p24 assays to assess viral protein content in the collected viral stocks. We also titrated the CMV-EGFP vector by infecting LNCaP cells to determine the corresponding tissue culture infection dose ( TCID ) with a defined p24 count. Viral aliquots with p24 counts of 3 ng were diluted up to 1/ 10 4 ( 0.3 being the lowest amount of p24 ) in 200 L of RPMI before infecting LNCaP cells (40% confluence ) in 24 -well plates. EGFP-positive cells were visualized and counted under a UV microscope. TCID was determined by the Karber method: n = À log e (1À p), in which n =average number of infectious virions per cell, p= proportion of EGFP -positive cells in the culture plates, and e =2.71828. Using this equation, 50% of cells infected in a given culture ( P= .5) indicated that a virus dose with an MOI of 0.693 was used [ À log e (1À 0.5) =0.693 ]. The average number of viral infectious units from these experiments was then used to convert p24 counts to the number of infecting virions in viral stocks. Our data indicate that a virus aliquot with 1 pg of p24 was equivalent to 1 -10 infectious virions, which is consistent with previous reports. 28 
Infection of cells by lentiviral vectors
Cells were plated in 24-well plates at 5000 cells /well 24 hours before infection. It was expected that cells would double in number by the time of infection. Various amounts of virus equivalent to 1Â10 4 to 1.2Â10 6 virions ( MOI 1 -120) were brought up to a volume of 0.5 mL with medium before addition to each well of cultured cells. The virus -containing medium from the infected wells was removed 16 hours postinfection, and fresh medium added.
Counting EGFP -positive cells
Four days after infection by the PSAP -lentiviral EGFP vector, the infected cell cultures were checked by UV microscopy visualization to detect individual positive cells. In the wells containing more than 5% positive cells, the cells were trypsinized and washed once with phosphate -buffered saline. The total number of cells and the percentage of EGFP-positive cells were then calculated by UV microscopy.
Use of nude mice to test the PSAP -EGFP lentiviral vector in vivo
LNCaP prostate cancer cells ( 2Â10 6 ) were mixed with 0.1 mL Matrigel (Fisher Scientific, Norcross, GA ) before subcutaneous injection into nude mice. Tumors with a diameter of approximately 0.7 cm were formed 14 days postinjection. Mice carrying tumors derived from the control tumor cell lines R11 or PC -3 were prepared by a similar procedure, except that no Matrigel was required for growing these tumor cell lines in nude mice. Approximately 2Â10 6 virions ( TCID 50 ) in 0.1 mL of serum -free RPMI medium were injected into each mouse intratumorally. The mice were sacrificed at day 7 postinjection of the lentiviral vector. Tumors recovered from mice were minced to pieces approximately 1 mm in diameter. The EGFP -positive cells were examined under a UV microscope.
RESULTS
Tissue -specific expression of the PSAP -lentiviral vector
Cell lines LNCaP, R11, DU145, HUVEC, and TU139 were infected with a lentiviral vector containing an RNA genome carrying the CMV-EGFP expression cassette. Significant EGFP expression ( > 50% positive cells) was demonstrated in all tested cells infected with a titer MOI of 40 (Fig 2A ) , suggesting that the VSV-G pseudotyped lentiviral vector is a highly efficient vector for infecting various human cells, consistent with other previously reported results. 24, 27 At very high titers of infection ( MOI 40 ), almost 100% of the cells became EGFPpositive, with a slight pathogenic effect seen in the infected cell cultures (approximately 5-25% cell death ). The cytopathic effects seen with high titers of lentiviral vector could be due to the presence of the VSV-G protein on the envelope of virions or on the small pieces of cell membrane that could pass through 0.22 -M filtration. ( Figs 3A and B ) . However, no significant YU, CHEN, CHIU, ET AL: PROSTATE -SPECIFIC LENTIVIRAL GENE THERAPY VECTOR cytopathic effects were demonstrated in the control cell lines ( Fig 3B) .
Apoptosis of LNCaP cells by the PSAP lentiviral vector
Although specific inhibition of protein synthesis by DTA binding to elongation factor 2 ( ELF2 ) has been demonstrated, the mechanism by which DTA induces cell death has not been clarified. Previous reports have suggested that DTA induces apoptosis. 20 The TUNEL staining method was used to examine infected LNCaP cells, and it was found that some cells underwent apoptosis. In the DTA vector -treated LNCaP cell culture, approximately 40% cells were detected as being apoptotic at 2 days postinfection, compared with only approximately 10% apoptotic cells in the untreated LNCaP cell culture. The high percentages of apoptotic cells partially explained the eradication effects of the LNCaP cells infected by the DTA lentiviral vector (Fig 3A ) .
Tissue -specific gene expression of the PSAP -EGFP lentiviral vector in nude mice
We also injected the PSAP -EGFP lentiviral vector into LNCaP tumors engrafted in nude mice intratumorally. Significant EGFP gene expression was detected in all the injected LNCaP tumors ( Fig 4 ) , whereas no EGFP -positive cells were detected in the control tumors that had been injected with the same viral stock in nude mice, including the R11 renal carcinoma cell line and PC -3, which is a non-PSA -producing prostate tumor cell line. We also tested the long -term pathogenic effects of lentiviral vectors by injecting nude mice with a higher dose (4Â10 6 virions ) of the lentiviral EGFP vector intratumorally, but found no significant pathogenic effects for three months.
DISCUSSION
Although the PSA promoter has been extensively studied, its promoter activity has not been fully characterized. Most reports have focused on responsiveness to androgen stimulation. 12 -14,29 -31 Absolute activity has not been clearly defined, because few studies have compared this promoter to well -characterized promoters such as the CMV promoter or the early promoter of simian virus 40 ( SV40 ). Thus, the feasibility of using this promoter for prostate cancer gene therapy is uncertain.
The PSA promoter used in this study was isolated from a patient with prostate cancer. DNA sequence analysis indicated that the patient -derived PSA promoter contains 15 mutations when compared to the Genbank sequence, HSU37672. 15 DNA transfection demonstrated that the promoter activity is approximately 5 -25% of that of the CMV promoter in a plasmid vector. 18, 20 At such levels of promoter activity, the PSA promoter succeeded in driving the DTA gene in prostate cancer cells, resulting in selective cell eradication by liposome-mediated gene transfection. 20 The drawback of using DNA vectors for cancer cell eradication is lower gene -delivery efficiency. Using liposome-mediated transfection, 5-20% cells are usually transfected in LNCaP prostate cell line cultures, but occasionally the amount can be less than 1%. Lower genedelivery efficiency may translate to lower performance in future gene therapy clinical trials, so development of other types of vectors is desirable.
We previously inserted the 1.4-kb PSA promoter with the luciferase gene into an adenoviral vector. Although expression levels were significantly increased, tissue specificity was decreased (data not shown). Results from other research groups are similar. 21 -23 Some reports suggest that inserting more positive regulatory sequences into adenoviral vectors could increase tissue specificity; 22 however, the sizes of the constructed promoters would be significantly larger ( > 3.5 kb ), which would not allow much room for inserting therapeutic genes. In addition, the tissue specificity of the PSA promoter in this adenoviral vector, approximately 20 -to 100 -fold, is still much lower than that of the lentiviral vector, as shown in this report. The decreased tissue specificity would likely increase vector toxicity when a suicide gene such as DTA serves as the therapeutic gene. 32, 33 Our lentiviral vector demonstrated satisfactory levels of gene -delivery efficiency in cell culture and in a nude mouse model. It is important to note that in this vector, the PSA promoter maintained its tissue specificity. These results indicate that for efficient and tissue -specific gene expression, the lentiviral vector is superior to either adenoviral vectors or DNA plasmids. Unlike the first or second generations of adenoviral vectors, the lentiviral vector retains only a very small fraction of viral sequences. Although the retained sequences of the viral LTR could function as promoters or enhancers of transcription, the absence of supporting proteins such as Tat and Rev abrogates the promoter and enhancer functions of the LTRs. As a result, the LTRs do not interfere with the PSA promoter in the lentiviral vector, and it maintains its tissue specificity. In adenoviral vectors, many viral sequences are retained, so the opposite is true. When adenoviral promoters and enhancers are involved with the PSA promoter, its tissue specificity is significantly decreased. A new type of adenoviral vector, the helper virus -dependent ( HD ) adenoviral vector, has recently been reported. 34 -36 The removal of adenoviral sequences that contain several nonspecific promoters and enhancers restores the specificity of tissue -specific promoters. 34 Potentially, HD virus also offers high tissue specificity when the PSAP -based gene expression cassette is inserted into this viral vector. However, thus far, no such results have been reported.
Because most prostate cancer cells grow slowly, meaning that only a small percentage of cancer cells are dividing at any given time that vectors are injected, the majority of cells, which are not dividing, will not be infected by nonlentiviral vectors. The relatively high efficiency of gene delivery by lentiviral vectors may be attributed to their capability to infect nondividing cells. Unlike other retroviruses, HIV-1 expresses genes in both dividing and nondividing cells, so the HIV-1-based lentiviral vector infects both dividing and nondividing cells. YU, CHEN, CHIU, ET AL: PROSTATE -SPECIFIC LENTIVIRAL GENE THERAPY VECTOR One limitation in using the lentiviral vector for gene delivery is that it is difficult to obtain high -titer viral stocks by current cotransfection methods. In the studies described here, it was found that viral titers in medium from cotransfected 293T cells were approximately 10 6 / mL, which is about 10 4 -fold lower than from adenoviral stocks. 25, 37, 38 Biosafety is another important consideration. Although theoretically the probability of generating a replication -competent HIV by three -piece cotransfection is rare ( there is no HIV-1 viral envelope gene in the three plasmids used for cotransfection ), and no report has yet demonstrated that any HIV molecules are generated from cotransfected 293T cells, the presence of HIV-1 genes and sequences during preparation of lentiviral vectors may be an important concern. Thus, a means of preparing high -titer lentiviral vectors and a safer method to generate them must be further refined in future studies.
The high infectivity of VSV-G protein -pseudotyped lentiviral vectors provides efficacious gene delivery. However, certain sensitive cells, including germline cells, may also be susceptible to the lentiviral vector. However, because most patients with prostate cancer are over 50 years of age, infection of germline cells may not pose a serious problem when using lentiviral vectors in treatments of prostate cancer.
The PSAR -PCPSA promoter has certain limitations in that it works only in cells producing PSA. Data from our laboratory and others have demonstrated that the metastatic cells of some patients may not produce PSA mRNA, 17, 39 so it would be ineffectual in these cases. Identification of other prostate -specific genes and promoters would thus be necessary to target cancer cells in these patients.
Because lentiviral vectors are covered by an envelope that is derived from the membrane of the host cells, potentially we can prepare lentiviral vector from cells derived from patients. The lentiviral vectors generated would have a viral envelope with membrane proteins almost identical to the cell membrane of the patient, except for the presence of VSV-G. We expect that immunoresponse against lentiviral vectors prepared from autologous cells will be much weaker compared with viral vectors from allogeneic cells. Using nonhuman primates as animal models to test the immunoresponse against lentiviral vectors will be necessary to clarify the interaction between lentiviral gene therapy vectors and the host immune system. 
